These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

483 related articles for article (PubMed ID: 17664404)

  • 1. Galantamine treatment of vascular dementia: a randomized trial.
    Auchus AP; Brashear HR; Salloway S; Korczyn AD; De Deyn PP; Gassmann-Mayer C;
    Neurology; 2007 Jul; 69(5):448-58. PubMed ID: 17664404
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Donepezil preserves cognition and global function in patients with severe Alzheimer disease.
    Black SE; Doody R; Li H; McRae T; Jambor KM; Xu Y; Sun Y; Perdomo CA; Richardson S
    Neurology; 2007 Jul; 69(5):459-69. PubMed ID: 17664405
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Galantamine prolonged-release formulation in the treatment of mild to moderate Alzheimer's disease.
    Brodaty H; Corey-Bloom J; Potocnik FC; Truyen L; Gold M; Damaraju CR
    Dement Geriatr Cogn Disord; 2005; 20(2-3):120-32. PubMed ID: 15990426
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomised trial.
    Erkinjuntti T; Kurz A; Gauthier S; Bullock R; Lilienfeld S; Damaraju CV
    Lancet; 2002 Apr; 359(9314):1283-90. PubMed ID: 11965273
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Atomoxetine augmentation of cholinesterase inhibitor therapy in patients with Alzheimer disease: 6-month, randomized, double-blind, placebo-controlled, parallel-trial study.
    Mohs RC; Shiovitz TM; Tariot PN; Porsteinsson AP; Baker KD; Feldman PD
    Am J Geriatr Psychiatry; 2009 Sep; 17(9):752-9. PubMed ID: 19700948
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A 2-year open-label study of galantamine therapy in Chinese Alzheimer's disease patients in Hong Kong.
    Chu LW; Yik PY; Mok W; Chung CP
    Int J Clin Pract; 2007 Mar; 61(3):403-10. PubMed ID: 17313606
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Donepezil treatment of patients with MCI: a 48-week randomized, placebo-controlled trial.
    Doody RS; Ferris SH; Salloway S; Sun Y; Goldman R; Watkins WE; Xu Y; Murthy AK
    Neurology; 2009 May; 72(18):1555-61. PubMed ID: 19176895
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Galantamine for vascular cognitive impairment.
    Craig D; Birks J
    Cochrane Database Syst Rev; 2006 Jan; 2006(1):CD004746. PubMed ID: 16437493
    [TBL] [Abstract][Full Text] [Related]  

  • 9. AMPA potentiator treatment of cognitive deficits in Alzheimer disease.
    Chappell AS; Gonzales C; Williams J; Witte MM; Mohs RC; Sperling R
    Neurology; 2007 Mar; 68(13):1008-12. PubMed ID: 17389305
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Donepezil in vascular dementia: combined analysis of two large-scale clinical trials.
    Román GC; Wilkinson DG; Doody RS; Black SE; Salloway SP; Schindler RJ
    Dement Geriatr Cogn Disord; 2005; 20(6):338-44. PubMed ID: 16192723
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cyclandelate in the treatment of patients with mild to moderate primary degenerative dementia of the Alzheimer type or vascular dementia: experience from a placebo controlled multi-center study.
    Weyer G; Eul A; Milde K; Wierich W; Herrmann WM
    Pharmacopsychiatry; 2000 May; 33(3):89-97. PubMed ID: 10855459
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy study of galantamine in possible Alzheimer's disease with or without cerebrovascular disease and vascular dementia in Thai patients: a slow-titration regimen.
    Thavichachart N; Phanthumchinda K; Chankrachang S; Praditsuwan R; Nidhinandana S; Senanarong V; Poungvarin N
    Int J Clin Pract; 2006 May; 60(5):533-40. PubMed ID: 16700849
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cholinesterase inhibitors for vascular dementia and other vascular cognitive impairments: a network meta-analysis.
    Battle CE; Abdul-Rahim AH; Shenkin SD; Hewitt J; Quinn TJ
    Cochrane Database Syst Rev; 2021 Feb; 2(2):CD013306. PubMed ID: 33704781
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Galantamine treatment in Alzheimer's disease with cerebrovascular disease: responder analyses from a randomized, controlled trial (GAL-INT-6).
    Erkinjuntti T; Gauthier S; Bullock R; Kurz A; Hammond G; Schwalen S; Zhu Y; Brashear R
    J Psychopharmacol; 2008 Sep; 22(7):761-8. PubMed ID: 18308781
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rivastigmine for dementia associated with Parkinson's disease.
    Emre M; Aarsland D; Albanese A; Byrne EJ; Deuschl G; De Deyn PP; Durif F; Kulisevsky J; van Laar T; Lees A; Poewe W; Robillard A; Rosa MM; Wolters E; Quarg P; Tekin S; Lane R
    N Engl J Med; 2004 Dec; 351(24):2509-18. PubMed ID: 15590953
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of galantamine in patients with mild Alzheimer's disease.
    Orgogozo JM; Small GW; Hammond G; Van Baelen B; Schwalen S
    Curr Med Res Opin; 2004 Nov; 20(11):1815-20. PubMed ID: 15537482
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of donepezil in patients with more severe Alzheimer's disease: a subgroup analysis from a randomized, placebo-controlled trial.
    Feldman H; Gauthier S; Hecker J; Vellas B; Xu Y; Ieni JR; Schwam EM;
    Int J Geriatr Psychiatry; 2005 Jun; 20(6):559-69. PubMed ID: 15920715
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Management of patients with Alzheimer's disease plus cerebrovascular disease: 12-month treatment with galantamine.
    Bullock R; Erkinjuntti T; Lilienfeld S;
    Dement Geriatr Cogn Disord; 2004; 17(1-2):29-34. PubMed ID: 14560062
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Two galantamine titration regimens in patients switched from donepezil.
    Engedal K; Davis B; Richarz U; Han J; Schäuble B; Andreasen N
    Acta Neurol Scand; 2012 Jul; 126(1):37-44. PubMed ID: 21992111
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A multicentre, randomized, double-blind, placebo-controlled study to evaluate the efficacy, tolerability and safety of two doses of metrifonate in patients with mild-to-moderate Alzheimer's disease: the MALT study.
    Dubois B; McKeith I; Orgogozo JM; Collins O; Meulien D
    Int J Geriatr Psychiatry; 1999 Nov; 14(11):973-82. PubMed ID: 10556869
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.